Rothschild Capital Partners LLC Acquires New Position in Tema Heart & Health ETF $HRTS

Rothschild Capital Partners LLC purchased a new stake in shares of Tema Heart & Health ETF (NASDAQ:HRTS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 24,512 shares of the company’s stock, valued at approximately $651,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jane Street Group LLC lifted its holdings in shares of Tema Heart & Health ETF by 9.4% in the 2nd quarter. Jane Street Group LLC now owns 37,164 shares of the company’s stock worth $1,062,000 after purchasing an additional 3,202 shares during the last quarter. Stifel Financial Corp increased its position in Tema Heart & Health ETF by 19.8% in the 4th quarter. Stifel Financial Corp now owns 33,647 shares of the company’s stock valued at $1,187,000 after acquiring an additional 5,571 shares during the period. Royal Bank of Canada raised its stake in Tema Heart & Health ETF by 8.8% during the 1st quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock valued at $710,000 after acquiring an additional 1,703 shares in the last quarter. Citadel Advisors LLC acquired a new position in Tema Heart & Health ETF during the 3rd quarter worth $243,000. Finally, JPMorgan Chase & Co. acquired a new position in Tema Heart & Health ETF during the 2nd quarter worth $63,000.

Tema Heart & Health ETF Stock Performance

NASDAQ:HRTS opened at $37.64 on Monday. The stock has a market cap of $56.08 million, a price-to-earnings ratio of 22.06 and a beta of 0.63. Tema Heart & Health ETF has a 1 year low of $29.45 and a 1 year high of $38.87. The business has a fifty day moving average of $36.89 and a 200-day moving average of $35.15.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.